. 2016 Dec 22;66(4):441–449. doi: 10.1007/s00262-016-1944-0

Table 4.

Dynamic changes under treatment

Factor	Categories	Week 4 compared to baseline		Week 12 compared to baseline
Factor	Categories	N (%)	p value	N (%)	p value
Absolute lymphocyte counts	Increase	13 (86.7)	0.003	5 (50.0)	0.721
Absolute lymphocyte counts	Decrease	2 (13.3)	0.003	5 (50.0)	0.721
Relative lymphocyte counts	Increase	12 (80.0)	0.036	4 (40.0)	1.00
Relative lymphocyte counts	Decrease	3 (20.0)	0.036	6 (60.0)	1.00
Absolute eosinophil counts	Increase	15 (100)	0.001	7 (70.0)	0.114
Absolute eosinophil counts	Decrease	0 (0.0)	0.001	3 (30.0)	0.114
Absolute monocyte counts	Increase	5 (33.3)	0.233	6 (60.0)	0.203
Absolute monocyte counts	Decrease	10 (66.7)	0.233	4 (40.0)	0.203
Lin⁻CD14⁺HLA-DR^−/low MDSCs	Increase	3 (37.5)	0.263	3 (60.0)	0.225
Lin⁻CD14⁺HLA-DR^−/low MDSCs	Decrease	5 (62.5)	0.263	2 (40.0)	0.225
CD4⁺CD25⁺FoxP3⁺ Tregs	Increase	7 (100)	0.018	1 (100)	n.a.
CD4⁺CD25⁺FoxP3⁺ Tregs	Decrease	0 (0.0)	0.018	0 (0.0)	n.a.

MDSCs myeloid-derived suppressor cells, Tregs regulatory T cells, n.a not applicable